Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132498 | 1.00 | HRH3 (0.61) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132837 | 1.00 | HRH3 (0.61) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132762 | 0.88 | HRH3 (0.49) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132267 | 0.87 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132223 | 0.87 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132220 | 0.87 | HRH3 (0.64) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL9204223 | 0.87 | HRH3 (0.73) | HRH3NPC1RAB9AKMT2ACRBN | |
| SCHEMBL6132366 | 0.87 | HRH3 (0.49) | HRH3NPC1RAB9AKMT2A | |
| SCHEMBL6132424 | 0.87 | HRH3 (0.49) | HRH3NPC1RAB9AKMT2A | |
| SCHEMBL9210226 | 0.86 | HRH3 (0.72) | HRH3NPC1RAB9AKMT2ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | HRH3 2597/4885NPC1 2414/4885RAB9A 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.